<DOC>
	<DOCNO>NCT00984204</DOCNO>
	<brief_summary>The purpose study demonstrate ablation Therapy™ Cool Path™ Duo cardiac ablation system eliminate typical atrial flutter use result unacceptable risk serious adverse event ( SAE 's ) .</brief_summary>
	<brief_title>Clinical Evaluation Therapy™ Cool Path™ Duo Cardiac Ablation System Treatment Typical Atrial Flutter ( AFL )</brief_title>
	<detailed_description>This prospective , multi-center , non-randomized study ( historical data control ) evaluate safety efficacy Therapy TM Cool PathTM Duo Ablation System treatment typical atrial flutter ( Cavo-triscupid isthmus dependent )</detailed_description>
	<mesh_term>Atrial Flutter</mesh_term>
	<criteria>A signed write Informed Consent Presence typical atrial flutter ( cavotricuspid isthmus dependent ) If subject receive antiarrhythmic drug therapy ( Class I Class III AAD ) arrhythmia typical atrial flutter , subject need control medication least 3 month . If subject typical atrial flutter start AAD ( ) ( Class I Class III ) subsequently another arrhythmia ( i.e . atrial fibrillation ) , 3 month AAD criterion apply . One document occurrence study arrhythmia document ECG , Holter , telemetry strip , transtelephonic monitor within past 6 month In good physical health 18 year age old Agree comply followup visit evaluation Prior typical atrial flutter ablation treatment Pregnancy Atypical flutter scar flutter ( nonisthmus dependent ) Significant coronary heart disease heart failure ; unstable angina pectoris and/or uncontrolled congestive heart failure ( NYHA Class III IV ) time enrollment A recent myocardial infarction within 3 month intend procedure date Permanent coronary sinus pace lead Tricuspid valvular disease require surgery and/or prosthetic tricuspid heart valve ( i.e . significant ) Evidence intracardiac thrombus history clot disorder Participation another investigational study Cardiac surgery within 1 month intend procedure date Allergy contraindication Heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>cavo-tricuspid dependent</keyword>
</DOC>